Physician profile
Ehsan Azimi
NPI 1215457015
$5,730.85
in general payments reported to CMS, 2019-2025
26 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.61 · 2021: $181 · 2022: $880 · 2023: $1,367 · 2024: $2,113 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,386.41 | 2021-2025 | Rinvoq, Skyrizi, Botox |
| Genzyme Corporation | $507.49 | 2021-2025 | |
| Janssen Biotech, INC. | $397.96 | 2022-2025 | Tremfya |
| Incyte Corporation | $394.90 | 2021-2025 | Opzelura |
| Ucb, INC. | $393.67 | 2022-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $293.40 | 2022-2025 | Aklief, Nemluvio |
| Sun Pharmaceutical Industries INC. | $269.43 | 2021-2025 | Winlevi |
| Arcutis Biotherapeutics, INC. | $265.58 | 2023-2025 | Zoryve |
| Amgen INC. | $264.62 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $256.19 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $230.83 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $212.76 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $195.05 | 2022-2024 | Adbry |
| Lilly USA, LLC | $164.75 | 2021-2025 | Olumiant, Taltz, Zepbound |
| Janssen Pharmaceuticals, INC | $79.61 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $78.51 | 2021-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $75.07 | 2025 | |
| Mimedx Group, INC. | $43.99 | 2024 | |
| Almirall LLC | $37.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.98 | 2024 | Sotyktu |
| Organon LLC | $34.53 | 2025 | Vtama |
| Dermavant Sciences, INC. | $24.13 | 2024 | Vtama |
| Blueprint Medicines Corporation | $23.97 | 2023 | Ayvakit |
| Epi Health, LLC | $23.86 | 2022 | |
| Stryker Corporation | $22.06 | 2024 | Variax |
| Medimetriks Pharmaceuticals, INC. | $18.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehsan Azimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.